One of the most dramatic examples of success in this area has been the use of poly-ADP-ribose polymerase (PARP) inhibitors in the treatment of patients with tumours that harbour inactivating mutations in the breast and ovarian cancer susceptibility genes, BRCA1 and BRCA2. Here, BRCA2 is linked to ovarian carcinoma.